Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Bruce Downey sold 13,000 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $14.51, for a total value of $188,630.00. Following the completion of the sale, the director now directly owns 41,234 shares in the company, valued at $598,305.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ MNTA traded up $0.31 during trading hours on Thursday, hitting $14.08. The company had a trading volume of 5,905 shares, compared to its average volume of 738,300. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $9.55 and a fifty-two week high of $32.20. The firm has a market capitalization of $1.44 billion, a PE ratio of -6.95 and a beta of 2.24.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.39. The company had revenue of $42.80 million for the quarter, compared to analyst estimates of $17.11 million. Momenta Pharmaceuticals had a negative return on equity of 47.74% and a negative net margin of 232.92%. The company’s quarterly revenue was down 33.7% compared to the same quarter last year. During the same period last year, the company earned $0.18 earnings per share. On average, equities research analysts predict that Momenta Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

MNTA has been the topic of several analyst reports. ValuEngine lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. BidaskClub lowered Momenta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 13th. Zacks Investment Research raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Thursday, January 3rd. JPMorgan Chase & Co. lowered Momenta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Friday, January 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. Momenta Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $22.03.

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Momenta Pharmaceuticals by 26.7% during the fourth quarter. Geode Capital Management LLC now owns 1,059,114 shares of the biotechnology company’s stock valued at $11,692,000 after purchasing an additional 223,085 shares during the period. Norges Bank acquired a new position in shares of Momenta Pharmaceuticals during the fourth quarter valued at $19,673,000. Dimensional Fund Advisors LP increased its holdings in shares of Momenta Pharmaceuticals by 10.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,118,942 shares of the biotechnology company’s stock valued at $12,353,000 after purchasing an additional 103,474 shares during the period. FMR LLC increased its holdings in shares of Momenta Pharmaceuticals by 25.7% during the fourth quarter. FMR LLC now owns 14,770,728 shares of the biotechnology company’s stock valued at $163,069,000 after purchasing an additional 3,023,513 shares during the period. Finally, Amalgamated Bank acquired a new position in shares of Momenta Pharmaceuticals during the fourth quarter valued at $136,000. 95.08% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Director Bruce Downey Sells 13,000 Shares of Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2019/03/21/momenta-pharmaceuticals-inc-mnta-director-bruce-downey-sells-13000-shares-of-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Article: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.